BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTHCARE CONFERENCE

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will have its President and CEO, Chuck Kummeth, present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 2:40 p.m. PST. Interested parties can access a live webcast via the company’s Investor Relations website.

Bio-Techne is a key player in creating purified proteins and reagent solutions, with products that cater to biomedical researchers and clinical laboratories. In fiscal 2021, Bio-Techne reported approximately $931 million in net sales. The company has around 2,700 employees globally.

MINNEAPOLIS, May 2, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:40 p.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $931 million in net sales in fiscal 2021 and has approximately 2,700 employees worldwide.

Contact:  David Clair, Senior Director, Investor Relations & Corporate Development
                david.clair@bio-techne.com
                612-656-4416  

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-bofa-securities-healthcare-conference-301536140.html

SOURCE Bio-Techne Corporation

FAQ

What is Bio-Techne's stock symbol?

Bio-Techne's stock symbol is TECH.

When will Bio-Techne present at the BofA Securities Healthcare Conference?

Bio-Techne will present at the BofA Securities Healthcare Conference on May 11, 2022, at 2:40 p.m. PST.

How can I access the Bio-Techne conference presentation?

You can access the live webcast of Bio-Techne's presentation on their Investor Relations website.

What were Bio-Techne's net sales in fiscal 2021?

Bio-Techne generated approximately $931 million in net sales in fiscal 2021.

How many employees does Bio-Techne have?

Bio-Techne has approximately 2,700 employees worldwide.